Intravenous anti-obsessive agents: a review.
Oral antidepressants are currently the first-line pharmacotherapy for obsessive-compulsive disorder (OCD), but response rates can often be low and with delayed onset of therapeutic action. Some reports have suggested that intravenous (i.v.) anti-obsessive agents may have faster onset of action and greater efficacy. A Medline search was conducted for all reports pertaining to the use of i.v. antidepressants for OCD. Search terms included: 'intravenous', 'clomipramine', 'selective serotonin reuptake inhibitor', 'tricyclic', 'citalopram', 'sertraline', 'paroxetine', 'fluvoxamine', 'SSRIs' and 'intravenous antidepressants'. Relevant articles mainly investigated clomipramine (CMI) with one open trial examining citalopram. Intravenous agents appear to be well-tolerated, particularly in those who have failed oral agents, and may act more rapidly to produce initial clinical response, although this advantage is often lost over time. Preliminary evidence suggests subgroups of patients with severe treatment-refractory OCD may benefit from i.v. anti-obsessive agents, CMI and citalopram. Larger, controlled trials are needed for more definitive conclusions.
Ravindran
L N
LN
Department of Psychiatry, VA San Diego Health Care System, San Diego, California, USA. arun_ravindran@camh.net
Jung
S M
SM
Ravindran
A V
AV
D000928:Antidepressive Agents / Q000008:administration & dosage*; D015283:Citalopram / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D002997:Clomipramine / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D006801:Humans; D007262:Infusions, Intravenous / Q000009:adverse effects / Q000379:methods; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy*; D020551:Pulse Therapy, Drug / Q000379:methods; D013997:Time Factors
D000928:Antidepressive Agents; D015283:Citalopram; D002997:Clomipramine